
BBIO Stock Forecast & Price Target
BBIO Analyst Ratings
Bulls say
BridgeBio Pharma is positioned for positive growth and profitability in the future, with strong results for Attruby and multiple future drug launches. While there are potential risks such as competition and clinical trial setbacks, the company has secured funding and is focused on developing treatments for rare genetic diseases with potential for expanding treatment into other conditions, making it an attractive investment opportunity.
Bears say
BridgeBio Pharma is currently facing significant regulatory and competitive risks, with multiple programs in active regulatory review and potential competition from existing products and product candidates in development. Additionally, the company has incurred a significant amount of debt, which could affect its ability to pursue its strategies and lead to negative impacts on its performance if its core programs are not successful. There are also inherent risks in the biotechnology sector, including clinical and commercial risks, as well as the constant need for significant amounts of capital to fund development.
This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
BBIO Analyst Forecast & Price Prediction
Start investing in BBIO
Order type
Buy in
Order amount
Est. shares
0 shares